Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal

J. Alarcão; R. Ascenção; J. Costa; M. Gouveia; M. Borges

doi:10.1016/j.jval.2018.09.618

Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal

J. Alarcão
, R. Ascenção
, J. Costa
, M. Gouveia
, M. Borges

Resultado de pesquisa › revisão de pares

Idioma original	English
Páginas (de-até)	S104-S104
Número de páginas	1
Revista	Value in Health
Volume	21
DOIs	https://doi.org/10.1016/j.jval.2018.09.618
Estado da publicação	Publicado - out. 2018
Evento	ISPOR Europe 2018: New perspectives for improving 21st century health systems - Centre Convencions Internacional de Barcelona, Barcelona Duração: 10 nov. 2018 → 14 nov. 2018

Acesso ao documento

10.1016/j.jval.2018.09.618

Citação

@article{b3fa4055fff740249a004cced8803145,

title = "Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal",

keywords = "Heart failure, Cost-effectiveness, Angiotensin-converting enzyme inhibitors, Angiotensin receptor neprilysin inhibitor, Sacubitril/valsartan",

author = "J. Alarc{\~a}o and R. Ascen{\c c}{\~a}o and J. Costa and M. Gouveia and M. Borges",

year = "2018",

month = oct,

doi = "10.1016/j.jval.2018.09.618",

language = "English",

volume = "21",

pages = "S104--S104",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Ltd.",

note = "ISPOR Europe 2018 : New perspectives for improving 21st century health systems ; Conference date: 10-11-2018 Through 14-11-2018",

}

TY - JOUR

T1 - Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal

AU - Alarcão, J.

AU - Ascenção, R.

AU - Costa, J.

AU - Gouveia, M.

AU - Borges, M.

PY - 2018/10

Y1 - 2018/10

KW - Heart failure

KW - Cost-effectiveness

KW - Angiotensin-converting enzyme inhibitors

KW - Angiotensin receptor neprilysin inhibitor

KW - Sacubitril/valsartan

U2 - 10.1016/j.jval.2018.09.618

DO - 10.1016/j.jval.2018.09.618

M3 - Meeting Abstract

SN - 1098-3015

VL - 21

SP - S104-S104

JO - Value in Health

JF - Value in Health

T2 - ISPOR Europe 2018

Y2 - 10 November 2018 through 14 November 2018

ER -